Navigation Links
Yisheng Biopharma to Present at BioPharma Asia Convention 2017 in Singapore
Date:3/15/2017

BEIJING, March 15, 2017 /PRNewswire/ -- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced that the company will present at annual BioPharma Asia Convention 2017 at Suntec Convention Center, Singapore.  The presentation is scheduled for 12:40 PM local time on March 22, 2017.

The management of Yisheng Biopharma will provide its business update on clinical progress of immuno-oncology therapeutics, vaccine products as well as commercialization strategies in Asia, USA and Europe.  

About Yisheng Biopharma Co., Ltd.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company headquartered in Beijing, China, focusing on the research, development, manufacturing and sales and marketing of immunological and vaccine products, with approximately 1000 employees in China, USA and Singapore. 

www.yishengbio.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/yisheng-biopharma-to-present-at-biopharma-asia-convention-2017-in-singapore-300423941.html


'/>"/>
SOURCE Yisheng Biopharma Co., Ltd.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Yisheng Biopharma and the United States Army Medical Research Institute of Infectious Diseases Announce Collaboration on New Vaccine Against Ebola Virus
2. Samenwerking tussen Yisheng Biopharma en het United States Army Medical Research Institute of Infectious Diseases aan een nieuw vaccin tegen ebolavirus
3. Yisheng Biopharma und das United States Army Medical Research Institute of Infectious Diseases verkünden Zusammenarbeit an neuem Impfstoff gegen das Ebolavirus
4. Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant
5. Yisheng Biopharma maakt positief resultaat bekend van klinische onderzoeksfase I van nieuw rabiës vaccin met PIKA-adjuvans
6. Yisheng Biopharma Announces Completion of Phase I Clinical Study of a Novel Hepatitis B Vaccine with PIKA Adjuvant
7. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
8. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
9. Array BioPharma To Present At The Jefferies 2013 Global Healthcare Conference
10. New Prefillable Syringe System Offers Advanced Glass Technology for Biopharmaceutical Injectable Drug Delivery
11. TransCelerate BioPharma Inc. Reveals Collaborative Methodology for Risk-Based Monitoring of Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):